Atherosclerosis (AS) is a leading cause of cardiovascular mortality worldwide, often resulting from chronic endothelial injury and inflammation. Recently, long non-coding RNAs (lncRNAs) have emerged as essential regulators of vascular pathology. A breakthrough study highlights the LINC01094 atherosclerosis biomarker as a primary driver of vessel wall damage. By identifying this molecule, researchers have opened new doors for early diagnosis and targeted intervention in high-risk patients.

Mechanisms of LINC01094 in Vascular Health

The study found that LINC01094 levels are significantly higher in human carotid atherosclerotic plaques and serum samples. Furthermore, oxidized low-density lipoprotein (ox-LDL) induces its expression in aortic endothelial cells. This upregulation triggers a cascade of negative effects, including reduced cell viability and increased apoptosis. Consequently, the high expression of LINC01094 promotes the release of adhesion molecules and inflammatory cytokines that accelerate plaque formation.

Mechanistically, LINC01094 operates through a \"sponge\" mechanism that disrupts normal cellular defense. It binds to miR-218-5p, which typically protects the endothelium from excessive stress. When the LINC01094 atherosclerosis biomarker levels rise, it sequesters miR-218-5p, allowing the transcription factor SP1 to increase unchecked. This axis directly accelerates endothelial dysfunction and plaque progression. Therefore, silencing this specific lncRNA could potentially slow down the development of cardiovascular disease.

Clinical Predictive Value

In addition to its biological role, LINC01094 shows strong clinical promise as a diagnostic tool. It predicts the occurrence of atherosclerosis with 81.36% sensitivity and 90.00% specificity. Notably, logistic regression identified LINC01094 as an independent risk factor for AS. Doctors may eventually use this marker to screen asymptomatic patients more effectively. Future therapies targeting the miR-218-5p/SP1 axis might provide a novel approach to treating chronic vascular inflammation.

FAQs

What is the role of LINC01094 in atherosclerosis?

LINC01094 is a long non-coding RNA that promotes endothelial injury and inflammation. It acts by sponging miR-218-5p, which leads to the overactivation of the SP1 pathway and subsequent vascular damage.

How accurate is LINC01094 as a biomarker?

According to clinical data, LINC01094 has a sensitivity of 81.36% and a specificity of 90.00% for predicting atherosclerosis, making it a highly promising diagnostic tool for clinicians.

Can silencing LINC01094 help treat heart disease?

Yes, experimental evidence suggests that silencing LINC01094 can counter the negative effects of ox-LDL. This intervention restores endothelial cell viability and reduces inflammatory responses, which could slow plaque formation.

Disclaimer: This content is for informational and educational purposes only. It does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Yao S et al. The LINC01094 drives atherosclerosis endothelial injury and inflammation via the miR-218-5p/SP1 axis and servers as a clinical biomarker. Eur J Med Res. 2026 Mar 07. doi: 10.1186/s40001-026-04060-1. PMID: 41795118.

Mao Y et al. Anti-atherosclerotic role of microRNA-218-5p via regulating the TNFRSF11A/NF-κB/NLRP3/caspase-1 pyroptosis pathway. Hum Cell. 2026 Jan 23. doi: 10.1007/s10616-026-00897-w. PMID: 41583385.

Ke X et al. MicroRNA-218-5p regulates inflammation response via targeting TLR4 in atherosclerosis. BMC Cardiovasc Disord. 2023 Mar 08. doi: 10.1186/s12872-023-03124-y. PMID: 36890442.